Chongqing bids $93M for Bilthoven

China's Chongqing Zhifei Biological Products has bid $93 million (€65 million) in an auction of Dutch vaccine maker Bilthoven Biologicals, a spin-off of the Netherlands Vaccine Institute. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.